There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrote in the new report, which calls for the U.S.

The company has decided to switch gears following disappointing data for a monoclonal antibody targeting a rare maternal ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing the “extremely challenging financial markets.” ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically driven forms of excess weight.

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...